Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies

Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA), a major component of the genitourinary syndrome of menopause, due to the combined estrogen-depleting effects of chemotherapy, adjuvant hormone therapy, and menopause. Ospemifene is approved to treat VVA in...

Full description

Bibliographic Details
Main Authors: Mariella Lilue, Santiago Palacios, María del Carmen Pingarrón Santofimia
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2020-07-01
Series:Drugs in Context
Subjects:
breast cancer
ospemifene
vulvar and vaginal atrophy
Online Access:https://www.drugsincontext.com/experience-with-ospemifene-in-patients-with-vulvar-and-vaginal-atrophy-and-a-history-of-breast-cancer:-case-studies/

Internet

https://www.drugsincontext.com/experience-with-ospemifene-in-patients-with-vulvar-and-vaginal-atrophy-and-a-history-of-breast-cancer:-case-studies/

Similar Items